Biotechnology Analyst Biegler, along with Dr. Christos Vaklavas discuss the HR+ metastatic breast cancer landscape, expectations for upcoming initial data for RLY-2608 (PI3Kalpha), unmet need for oral SERD(s), and the impact of Enhertu on the HR+ space (relevant companies RLAY, ARVN, OLMA, AMAM, GILD, AZN, LLY) on an Analyst/Industry conference call to be held on March 27 at 2 pm.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RLAY:
- JMP Securities biotech analyst to hold an analyst/industry conference call
- Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
- Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
- Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences
